Xanadu Bio
PrivateLast Round
Series B
Aug 27, 2025
Total Funding Raised
$22.99M
Company Overview
Xanadu Bio is a biotechnology company that develops a biodegradable poly(amine-co-ester) nanoparticle delivery platform for mRNA and other nucleic acid therapeutics.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Xanadu Bio Comparables
Compare Xanadu Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Stradefy Biosciences | 83% | |
| Nanite, Inc. | 83% | |
| 20Med Therapeutics | 80% | |
Xanadu Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Aug 27, 2025 | ||||
| Series A | Aug 16, 2022 |
Key People
Founding team and executive leadership
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 27, 2025
$11M round completed.
- May 1, 2025
Monthly visitors increased 158% MoM, reaching 2.1K.
Xanadu Bio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Xanadu Bio's valuation, stock price, and market status.